ObsEva to Present Pharmacology Results Demonstrating OBE022 Exerts a Synergistic Effect in Combination with Standard of Care in Animal Model for Preterm Labor

– OBE022 is ObsEva’s potential first-in-class, oral and selective PGF2alpha receptor antagonist – Geneva, Switzerland – 17 March 2017 – ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company…